论文部分内容阅读
目的观察硼替佐米为主的治疗方案治疗多发性骨髓瘤(MM)的疗效和安全性及预后。方法选择2009年7月-2014年12月在该院血液科治疗的MM患者60例,按抽签法将患者分为硼替佐米组34例和常规组26例。常规组采用常规的化疗方案,硼替佐米组接受以硼替佐米为主的联合治疗方案。比较2组临床疗效、生存期及不良反应发生情况。结果硼替佐米组的总缓解率和总有效率明显高于常规组,生存期明显长于常规组,差异均有统计学意义(P<0.05)。2组患者对不良反应均可耐受,对症处理后均减轻。结论以硼替佐米为主的治疗方案能有效提高MM的临床缓解率和总有效率,且不良反应均可耐受,延长了患者的生存期,值得临床推广。
Objective To observe the efficacy, safety and prognosis of bortezomib-based treatment for multiple myeloma (MM). Methods Sixty patients with MM treated by hematology in our hospital from July 2009 to December 2014 were selected and randomly divided into bortezomib group (34 cases) and routine group (26 cases) by lottery method. Conventional chemotherapy was used in the conventional group, and the bortezomib group received the bortezomib-based combination regimen. The clinical efficacy, survival and adverse reactions in the two groups were compared. Results The total remission rate and total effective rate in bortezomib group were significantly higher than those in conventional group, and the survival rate was significantly longer than that in conventional group (P <0.05). Two groups of patients were tolerable adverse reactions, symptomatic treatment were reduced. Conclusion The bortezomib-based treatment regimen can effectively improve the clinical response rate and total effective rate of MM, and the adverse reactions can be tolerated, prolonging the survival of patients, worthy of clinical promotion.